Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Stage III or IV Malignant Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01826448
What this trial is testing

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Who this might be right for
V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Daiichi Sankyo 13
Testing effectiveness (Phase 2)WithdrawnNCT04703426
What this trial is testing

Sargramostim (GM-CSF) + PD-1

Who this might be right for
Unresectable MelanomaMetastatic MelanomaStage III Melanoma+1 more
Dana-Farber Cancer Institute
Not applicableStudy completedNCT01715077
What this trial is testing

Study of Ipilimumab in the Immune System

Who this might be right for
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
University Health Network, Toronto 4
Testing effectiveness (Phase 2)Looking for participantsNCT05428007
What this trial is testing

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
MelanomaUnresectable Melanoma
NYU Langone Health 105
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Not applicableLooking for participantsNCT04045691
What this trial is testing

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Who this might be right for
Melanoma Stage IVMelanoma Stage III
Pierre Fabre Pharma GmbH 750
Early research (Phase 1)Study completedNCT02935790
What this trial is testing

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Who this might be right for
Malignant Melanoma
Celgene 1
Early research (Phase 1)Study completedNCT00091143
What this trial is testing

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma (Skin)
Providence Cancer Center, Earle A. Chiles Research Institute 20
Large-scale testing (Phase 3)Looking for participantsNCT06624644
What this trial is testing

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Who this might be right for
Melanoma (Skin Cancer)Melanoma Stage IIIB-IVCutaneous Melanoma+1 more
Linnaeus Therapeutics, Inc. 135
Testing effectiveness (Phase 2)Ended earlyNCT03241927
What this trial is testing

Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

Who this might be right for
Melanoma
Nina Bhardwaj 1
Early research (Phase 1)Study completedNCT00217542
What this trial is testing

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Who this might be right for
Recurrent MelanomaRecurrent Renal Cell CancerStage III Melanoma+2 more
National Cancer Institute (NCI) 42
Very early researchStudy completedNCT03655756
What this trial is testing

PDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Who this might be right for
Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IV
TuHURA Biosciences, Inc. 7
Testing effectiveness (Phase 2)Study completedNCT00412828
What this trial is testing

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Unresectable Stage III or Stage IV Melanoma
CuraGen Corporation 117
Early research (Phase 1)Study completedNCT01245556
What this trial is testing

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 8
Testing effectiveness (Phase 2)Study completedNCT00700882
What this trial is testing

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Who this might be right for
Melanoma (Skin)
Eastern Cooperative Oncology Group 81
Testing effectiveness (Phase 2)Looking for participantsNCT05269381
What this trial is testing

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+98 more
Mayo Clinic 138
Early research (Phase 1)Study completedNCT01005472
What this trial is testing

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Who this might be right for
Metastatic Melanoma
Jonsson Comprehensive Cancer Center 16
Early research (Phase 1)Study completedNCT00815607
What this trial is testing

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Who this might be right for
Melanoma
Alaunos Therapeutics 12
Not applicableLooking for participantsNCT02828202
What this trial is testing

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

Who this might be right for
Malignant Melanoma
Assistance Publique - Hôpitaux de Paris 6,000
Testing effectiveness (Phase 2)Study completedNCT04526899
What this trial is testing

Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Who this might be right for
Melanoma Stage IIIMelanoma Stage IVUnresectable Melanoma
BioNTech SE 184
Next Page